Global Glaucoma Therapy Industry To 2026

DUBLIN, 22 October 2021 / PRNewswire / – The “Glaucoma Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2021-2026” the report was added to ResearchAndMarkets.com offer.

Research and Markets logo

The global glaucoma therapeutics market has reached a value of 6.8 billion US dollars in 2020. Going forward, the market is expected to grow at a CAGR of 6.3% during 2021-2026. Bearing in mind the uncertainties of COVID-19, the analyst continuously monitors and assesses the direct and indirect influence of the pandemic on different end-use sectors. This information is included in the report as a major contributor to the market.

Glaucoma therapy refers to various treatment alternatives for primary open-angle (POA) and closed-angle (CAP) glaucoma. The disease is characterized by structural changes in the optic nerves which usually lead to vision loss and blindness. Treatment of glaucoma can be initiated with topical eye drops, which consist primarily of beta-blockers, prostaglandin analogs, cholinergic carbonic anhydrase inhibitors, and alpha-adrenergic agonists. These eye drops minimize the production of fluid in the eyes, thereby reducing intraocular pressure (IOP). This can be followed by traditional or laser surgeries or a combination of the two, which use products such as implantable extended-release devices, polymer-based contact lenses, drug-eluting tear plugs, micro-needle injection devices and micro-dosing technologies.

One of the key factors driving the growth of the market is the increasing prevalence of glaucoma across the world. Glaucoma is very common in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataracts, and dry eyes. In this light, the increase in the geriatric population, which is more susceptible to such diseases, creates positive prospects for the growth of the market. In addition, the growing health awareness among the masses and the growing preference for laser glaucoma surgery is also driving the growth of the market. In addition, the development of innovative combined excavations acts as another growth factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogues in combination with two or more drugs to control high IOP levels. Other factors, including the advent of advanced glaucoma diagnostic techniques, as well as improved healthcare infrastructure, are expected to further drive the market.

Competitive landscape

The report also analyzed the competitive landscape of the market with some of the major players being Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG , Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI SpA and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report

  • How has the global glaucoma therapeutics market performed so far and how will it perform in the years to come?

  • What has been the impact of COVID-19 on the global glaucoma therapeutics market?

  • What are the main regional markets?

  • What is the market split according to the class of drugs?

  • How does the market break up depending on the indication?

  • What is the distribution of the market according to the end user?

  • What are the different stages of the industry value chain?

  • What are the main factors and challenges for the industry?

  • What is the structure of the global glaucoma therapeutics market and who are the major players?

  • How competitive is the industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Glaucoma Therapy Market
5.1 Market overview
5.2 Market performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market breakdown by drug class
6.1 Prostaglandin analogues
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Beta-blockers
6.2.1 Market trends
6.2.2 Market Forecast
6.3 Alpha-adrenergic agonists
6.3.1 Market trends
6.3.2 Market Forecast
6.4 Carbonic anhydrase inhibitors
6.4.1 Market trends
6.4.2 Market Forecast
6.5 Combination drugs
6.5.1 Market trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market trends
6.6.2 Market Forecast

7 Market breakdown by indication
7.1 Open-angle glaucoma
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Angle-closure glaucoma
7.2.1 Market trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market trends
7.3.2 Market Forecast

8 Market breakdown by end user
8.1 Hospitals
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Eye clinics
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Outpatient surgery centers
8.3.1 Market trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market trends
8.4.2 Market Forecast

9 Market breakdown by region

10 SWOT Analysis

11 Value chain analysis

Analysis of the five forces of 12 carriers

13 Price analysis

14 Competitive landscape
14.1 Market structure
14.2 Key players
14.3 Profiles of key players
14.3.1 Aerie Pharmaceuticals Inc.
14.3.1.1 Company presentation
14.3.1.2 Product portfolio
14.3.1.3 Finances
14.3.2 Allergan SA
14.3.2.1 Company presentation
14.3.2.2 Product portfolio
14.3.2.3 Finances
14.3.2.4 SWOT Analysis
14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
14.3.3.1 Company overview
14.3.3.2 Product portfolio
14.3.3.3 SWOT Analysis
14.3.4 Inotek Pharmaceuticals Corp.
14.3.4.1 Company overview
14.3.4.2 Product portfolio
14.3.5 Merck & Co. Inc.
14.3.5.1 Company overview
14.3.5.2 Product portfolio
14.3.5.3 Finances
14.3.5.4 SWOT Analysis
14.3.6 Novartis AG
14.3.6.1 Company overview
14.3.6.2 Product portfolio
14.3.6.3 Finances
14.3.6.4 SWOT Analysis
14.3.7 Pfizer Inc.
14.3.7.1 Company overview
14.3.7.2 Product portfolio
14.3.7.3 Finances
14.3.7.4 SWOT Analysis
14.3.8 Santen Pharmaceutical Co. Ltd.
14.3.8.1 Company overview
14.3.8.2 Product portfolio
14.3.8.3 Finances
14.3.8.4 SWOT Analysis
14.3.9 SIFI SpA
14.3.9.1 Company overview
14.3.9.2 Product portfolio
14.3.9.3 Finances
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company overview
14.3.10.2 Product portfolio
14.3.10.3 Finances
14.3.10.4 SWOT Analysis

For more information on this report, visit https://www.researchandmarkets.com/r/np7jjm

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

Cision

Cision

Show original content:https://www.prnewswire.com/news-releases/worldwide-glaucoma-therapeutics-industry-to-2026—featuring-novartis-pfizer-and-sifi-among-others-301406819.html

SOURCE Research and Markets


Source link

Comments are closed.